Risdiplam

6 trials 3 recruiting MMusculoskeletal Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

2 Sponsors

7 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 3 Phase IV: 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Spinal muscular atrophy 6

Sponsors using this IMP

F. Hoffmann-La Roche AG 5 UZ Leuven 1

All trials

6 total

A Study to Evaluate the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients with Spinal Muscular Atrophy who Experience… Recruiting

2023-505161-81-00 Phase IV 2 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients with Spinal Muscul… Recruiting

2023-504508-26-00 Phase IV 2 countries F. Hoffmann-La Roche AG
A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular Atrophy Recruiting

2023-505602-42-00 Phase II 6 countries F. Hoffmann-La Roche AG
A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy Ended

2023-506009-20-00 Phase II 2 countries F. Hoffmann-La Roche AG
Outcome measures in SMA patients treated with Risdiplam. Ended

2022-501760-17-00 Phase III 1 country UZ Leuven
A study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Risdiplam in adult and pediatric patients with spi… Ended

2023-506739-14-00 Phase II 5 countries F. Hoffmann-La Roche AG

Showing 1–6 of 6 trials

← All drugs A–Z